SCHEDULE 13D/A: ADAR1 Capital Management Urges Keros Therapeutics to Restructure and Return Cash, Vows to Withhold Votes for Directors

ADAR1 Capital Management, Keros Therapeutics' largest shareholder, has publicly outlined proposals to maximize shareholder value, including business restructuring, cash returns, and optimizing the Takeda partnership, while announcing its intent to withhold votes for two current directors.

Summary

• ADAR1 Capital Management, LLC, along with its affiliates, is the largest stockholder of Keros Therapeutics, holding approximately 13.3% of the company's outstanding shares.
• As of May 12, 2025, ADAR1 Capital Management, LLC and Daniel Schneeberger beneficially own 5,390,964 shares, representing 13.27% of Keros Therapeutics' Common Stock.
• ADAR1 Capital Management GP, LLC beneficially owns 4,647,406 shares, representing 11.44% of the Common Stock.
• The percentage ownership is based on 40,615,414 shares of Common Stock outstanding as of May 1, 2025, as reported in Keros Therapeutics' Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• ADAR1 has issued a press release and investor presentation outlining proposals to maximize value for Keros stockholders.
• Key proposals include restructuring the business and reducing costs, returning excess cash to stockholders, and optimizing the value of the Issuer's partnership with Takeda Pharmaceuticals.
• ADAR1 intends to vote 'WITHHOLD' on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Board of Directors at the upcoming Annual Meeting of Stockholders.
• The Annual Meeting of Stockholders is scheduled for June 4, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative for Keros Therapeutics' current management and strategy, as indicated by the activist investor's public challenge and intent to withhold votes. However, it carries a potential for positive change if ADAR1's proposals are adopted, which could unlock value for shareholders.

Positives

• ADAR1 Capital Management, as the largest shareholder, is actively advocating for strategies aimed at maximizing shareholder value.
• Proposals to restructure the business and reduce costs could lead to improved operational efficiency and profitability.
• The suggestion to return excess cash to stockholders indicates a focus on shareholder returns.
• Efforts to optimize the Takeda Pharmaceuticals partnership could unlock additional value from a key strategic alliance.

Negatives

• The activist stance by ADAR1 Capital Management indicates dissatisfaction with the current management and strategic direction of Keros Therapeutics.
• The intention to withhold votes for two current directors, Dr. Mary Ann Gray and Dr. Alpna Seth, signals a potential for board-level conflict and instability.
• Public criticism and demands for change can create uncertainty for investors and potentially distract management from core operations.

Risks

• Potential for ongoing conflict between ADAR1 Capital Management and Keros Therapeutics' current board and management, which could hinder strategic execution.
• Uncertainty regarding the outcome of the Annual Meeting and whether ADAR1's proposals will be adopted or if their desired board changes will occur.
• Risk that proposed restructuring and cost reduction efforts may negatively impact key operations or employee morale if not managed carefully.
• The success of 'optimizing' the Takeda partnership is not guaranteed and depends on various factors, including Takeda's cooperation.

Future Outlook

ADAR1 Capital Management's future outlook for Keros Therapeutics is contingent on the adoption of its proposed strategies, which include significant business restructuring, returning excess cash to shareholders, and optimizing the existing partnership with Takeda Pharmaceuticals. They believe these actions are necessary to maximize value for stockholders.

Management Comments

• "ADAR1 Capital Management today released an investor presentation outlining its rationale for withholding votes on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors at the Company’s upcoming Annual Meeting of Stockholders."
• "ADAR1 Capital Management's proposals to maximize value for the Issuer's stockholders include (i) restructuring the business and reducing costs, (ii) returning excess cash to stockholders, and (iii) optimizing value of the Issuer's partnership with Takeda Pharmaceuticals."
• "ADAR1 Capital Management reiterates its intention to vote 'WITHHOLD' on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Board at the Annual Meeting."

Industry Context

This filing represents a significant instance of shareholder activism within the biotechnology and life sciences sectors, a trend where large institutional investors increasingly challenge company management and boards to improve performance and unlock shareholder value. Such actions often arise in industries with high R&D costs and long development cycles, where capital allocation and strategic partnerships are critical. ADAR1's focus on cost reduction and optimizing partnerships reflects broader investor demands for greater financial discipline and clear pathways to profitability in the biotech space.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this filing, ADAR1's proposals align with common activist investor strategies seen across the biotech industry, such as demanding cost efficiencies and improved capital allocation, similar to campaigns by other activist funds targeting underperforming biopharmaceutical companies.
• The call for returning 'excess cash' to stockholders suggests ADAR1 believes Keros's current cash reserves are not being deployed optimally, a common critique in the biotech sector where companies often hold significant cash for R&D or M&A, but may face pressure to distribute it if growth prospects are unclear or valuations are depressed.
• The emphasis on 'optimizing' the Takeda partnership highlights the critical importance of strategic alliances in biotech. Successful partnerships, like those seen with major pharmaceutical companies, are often benchmarks for value creation, and ADAR1's focus implies a belief that the current arrangement is not yielding its full potential compared to best-in-class industry collaborations.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** Potential for increased shareholder value if ADAR1's proposals are adopted, but also risk of uncertainty and volatility due to activist campaign.
• **Management & Board:** Increased pressure and scrutiny from a major shareholder, potentially leading to changes in leadership or strategy.
• **Employees:** Potential for business restructuring and cost reductions could impact workforce, though specific details are not provided.
• **Partners (Takeda Pharmaceuticals):** Efforts to 'optimize' the partnership could lead to renegotiations or changes in the collaboration terms, potentially affecting the relationship.

Next Steps

• Keros Therapeutics' Annual Meeting of Stockholders is scheduled for June 4, 2025, where shareholders will vote on the re-election of directors, including Dr. Mary Ann Gray and Dr. Alpna Seth.
• ADAR1 Capital Management will continue to advocate for its proposals, including business restructuring, cost reduction, returning excess cash, and optimizing the Takeda partnership.

Key Dates

Keywords

Keros Therapeutics, ADAR1 Capital Management, Shareholder Activism, Corporate Governance, Proxy Fight, Biotechnology, Life Sciences, Shareholder Value, Cost Reduction, Cash Return, Takeda Pharmaceuticals, SEC Filing, Schedule 13D